FDA Approves a New Drug Type for Schizophrenia

The FDA recently approved Cobenfy, the first new type of drug for schizophrenia in years, targeting different brain receptors to reduce psychotic symptoms such as paranoia and disorganized thinking. Expected to have fewer side effects and a lower mortality risk, Cobenfy offers hope for patients who often stop current treatments due to side effects. This approval could be a significant treatment option for people with schizophrenia.